Global Genitourinary Drugs Market - 2021-2028
The global genitourinary drugs market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Genitourinary drugs are used to treat disorders affecting the kidneys, bladder, ureters, and urethra. Since long, patients suffering from disorders and infections related to genitourinary systems have been depending on steroids and immunosuppressant’s which are chemically synthesized and may reciprocate with some serious side effects such as insomnia, acne, nausea, vomiting, and diarrhea. As a result, patients are now turning to biological drugs that not only cause fewer to no side-effects, but are also more effective in the treatment of genitourinary infections.
The global genitourinary drugs market is driven by the increasing prevalence of genitourinary disorders, rising disposable incomes, and constant improvements in healthcare infrastructure will drive genitourinary drugs market.
The growing prevalence of genitourinary disorders is expected to drive the market growth
The growing prevalence of genitourinary disorders and increasing number of pipeline drugs are expected to widen the market growth, globally. In addition, the rising disposable incomes and constant improvements in healthcare infrastructure, increase in investments in R&D activities in developing novel molecules for the treatment of genitourinary diseases, and the increasing number of pipeline drugs are also expected to drive the market, during the forecast period. The vast array of pipeline drugs with a high probability of clearing clinical trials in the future. For instance, currently, 47 and 16 medications for cervical cancer are in clinical development phase and phase-II stages respectively, which exemplify the rapidly growing research platform.
The aforementioned factor is believed to be a consequence of collaborative research initiatives conducted by the major pharmaceutical companies consistently striving to strengthen their leadership position in the branded genitourinary drugs market space. For instance, in September 2016, Bristol-Myers Squibb announced its collaboration with Nektar Therapeutics to evaluate the combined efficacy of NKTR-214 and Opdivo (nivolumab) in treating five tumor types, including bladder cancer. These factors are driving the market growth in the forecast period.
The increasing prevalence of diabetes, is expected to drive the growth in the forecast period
Patients with diabetes are highly susceptible to suffer from urinary tract infections. Women are more disposed to this problem due to the short length of urethra that facilitates easier entry of microorganisms. Global prevalence of diabetes is projected to reach up to 552 million by 2030 from 366 million in 2011, as per the statistics by International Diabetes Federation. Tremendous growth in diabetes prevalence should also boost the demand for genitourinary drugs over the coming years. Urinary Tract Infections (UTIs) affect more than 150 million people every year worldwide, resulting in direct healthcare expenses of over USD 6 billion. Around 2.4 percent of women and men will be detected with bladder cancer at some point during their lifetime. These factors are driving the market growth in the forecast period.
Increasing number of counterfeit drugs is likely to hinder the market growth
However, an increasing number of counterfeit drugs and lack of awareness about the infections and drugs for the treatment are going to restrain the market for genitourinary drugs.
COVID-19 Impact Analysis
The impact Covid-19 has created in China and the lockdown in India, United States, and other countries, further increases the chances of shoot up in the cost of raw materials and drugs. 13% of the drug manufacturers are based out of China and according to the FDA, as of 2018, 24% of medicines and 31% of medical ingredients were imported from India. The profit for these types of drugs is very marginal and the supply chain is lean. The API plant for these are often overseas with India and China dominating the market. The problem at any stage can cause drug shortage with the average drug shortage lasting for 14 months and there are cases where it has lasted for 3 years even. These factors are restraning the growth of the market in the forecast period.
Urinary tract infections segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
As there is an increase in the incidence of urinary tract infections, the demand for genitourinary drugs increases, which, in turn helps in driving the overall market. Furthermore, the launch of combination drugs, development, and approval of new drugs, which are more efficient, and the increasing geriatric population are also expected to boost the growth of the urinary tract infection segment in the global genitourinary drugs market.
Urinary tract infection is more common in women compared to men due to their anatomy. Several women experience urinary tract infection more than once in their lifetime. According to certain studies, urinary tract infection affects approximately 150 million people globally. In addition, approximately 11% women visit one physician in a year for urinary tract infection treatment. Hormonal changes, improper personal hygiene, use of catheters, and other factors are some of the main causes of urinary tract infection. With an increase in the prevalence of urinary tract infection, the growth of the global genitourinary drugs market in the forecast period.
The hospital pharmacy are expected to dominate the genitourinary drugs market during the forecast period
The hospital pharmacies held the largest share in the genitourinary drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
North America region holds the largest market share global genitourinary drugs
North America dominated the market with the largest revenue share in 2020. The rise in genitourinary disease cases, growing need for improved treatments and therapies of genitourinary diseases and increasing awareness about genitourinary diseases is driving the growth of the market in the region. A quarter to a third of men and women in the U.S. suffer from urinary incontinence. That means millions of Americans.
The prevalence of chronic renal failure is also increasing in the country. For instance, more than 661,000 Americans have renal failure. Of these, 468,000 individuals are on dialysis, and roughly 193,000 live with a functioning kidney transplant. The R&D activities related to drug development, adding positive impetus to the demand spurt of genitourinary drugs. Thus the mention factors is driving the growth of the market in the forecast period.
The genitourinary drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AstraZeneca, Melinta Therapeutics Inc, Cipla USA Inc, Allergan PLC, Merck & Co. Inc., Pfizer Inc., Genentech, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Novartis AG, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the genitourinary drugs globally.
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
Product Portfolio: The Company’s portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.
Why Purchase the Report?
Visualize the composition of the genitourinary drugs segmentation by disease type, drug type, distribution channel, and region highlighting the key commercial assets and players.
Identify commercial opportunities in genitourinary drugs by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of genitourinary drugs- level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The global genitourinary drugs report would provide an access to an approximately 45+ market data table, 40+ figures and 180 pages.
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Global Genitourinary Drugs Market - By Disease Type
Urinary Tract Infections
Chronic renal failure
Global Genitourinary Drugs Market - By Drug Type
Urinary pH Modifiers
Miscellaneous Genitourinary Tract Agents
Global Genitourinary Drugs Market - By Distribution Channel
Global Genitourinary Drugs Market - By Region
Middle East & Africa
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook